Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 108 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severely Elevated Blood Pressure Clear all
Suspended Phase 4 Interventional

Ketamine for Sedation in Severe Traumatic Brain Injury

NCT06429657
View directory record Official record
Conditions
Severe Traumatic Brain Injury, Intracranial Hypertension, Intracranial Hemorrhage, Hypertensive
Interventions
Ketamine with propofol, Standard of Care propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam
Drug · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 30, 2026, 2:42 PM EDT
Not yet recruiting Phase 3 Interventional

Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure

NCT07220902
View directory record Official record
Conditions
Severe Preeclampsia, Eclampsia Preeclampsia
Interventions
Levetiracetam, magnesium sulfate
Drug
Lead sponsor
Nebraska Methodist Health System
Other
Eligibility
19 Years and older · Female only
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Sep 30, 2026, 2:42 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Severe Sepsis in Children - IMPRESS-C

NCT02598674
View directory record Official record
Conditions
Acute Kidney Injury, Chronic Kidney Disease, Hypertension
Interventions
Iodohippurate, 24 hour ambulatory Blood Pressure, Peripheral Arterial Tonometry, Pulse Wave Velocity, Gadolinium
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 30, 2026, 2:42 PM EDT
Recruiting Not applicable Interventional

External Lumbar Drainage to Reduce ICP in Severe TBI: a Phase 1 Clinical Trial

NCT05889650
View directory record Official record
Conditions
Severe Traumatic Brain Injury, Intracranial Hypertension
Interventions
External Lumbar drainage
Procedure
Lead sponsor
Brain Trauma Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Gainesville, Florida • Kansas City, Kansas • Dallas, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 30, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Brain Tissue Oxygen Monitoring in Traumatic Brain Injury (TBI)

NCT00974259
View directory record Official record
Conditions
Severe Traumatic Brain Injury
Interventions
Management protocol based on pBrO2 and ICP values., Management protocol based on ICP values only.
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
10
States / cities
Miami, Florida • Durham, North Carolina • Cincinnati, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Sep 30, 2026, 2:42 PM EDT
Not listed Not applicable Interventional

Study of an Intervention to Improve Problem List Accuracy and Use

NCT01105923
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer, Coronary Artery Disease, Congestive Heart Failure, Diabetes, Glaucoma, Hemophilia, Hypertension, Hyperthyroidism, Hypothyroidism, Myasthenia Gravis, Osteoporosis, Osteopenia, Renal Failure, Renal Insufficiency, Sickle Cell Disease, Stroke
Interventions
MAPLE
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Sep 30, 2026, 2:42 PM EDT
Completed Phase 3 Interventional

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension

NCT00095394
View directory record Official record
Conditions
Hypertension
Interventions
Irbesartan/HCTZ, Irbesartan monotherapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
156
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 153 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Sep 30, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension

NCT00327587
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan + amlodipine, Valsartan + HCTZ, Amlodipine + HCTZ, Valsartan + amlodipine + HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Sep 30, 2026, 2:42 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Finger Plethysmography to Predict Fluid Responsiveness in Healthy Pregnancy and Severe Preeclampsia

NCT07430254
View directory record Official record
Conditions
Pre-Eclampsia, Severe, Pregnancy
Interventions
Noninvasive finger plethysmographic cardiac output monitoring, Standard transthoracic echocardiographic assessment
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 30, 2026, 2:42 PM EDT
Terminated Phase 4 Interventional

Metformin and Esomeprazole in Preterm Pre-eclampsia

NCT06359015
View directory record Official record
Conditions
Preeclampsia Severe, Pre-Eclampsia, Preeclampsia, Preeclampsia Second Trimester, Preeclampsia Complicating Childbirth, Preeclampsia Puerperium, Preterm
Interventions
Metformin, Esomeprazole
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Sep 30, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension

NCT00046319
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
BSF 208075
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2009 · Synced Sep 30, 2026, 2:42 PM EDT
Completed Phase 3 Interventional

Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)

NCT00369837
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Montgomery, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Sep 30, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

Furosemide vs. Placebo for Severe Antepartum Hypertension

NCT04615624
View directory record Official record
Conditions
Pre-Eclampsia, Hypertension in Pregnancy, Pregnancy Complications, Hypertension, Pregnancy-Induced
Interventions
Furosemide, Placebo
Drug · Other
Lead sponsor
Melanie Maykin, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 30, 2026, 2:42 PM EDT
Completed Phase 1 Interventional Results available

Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension

NCT02587325
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Tucson, Arizona • Torrance, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 30, 2026, 2:42 PM EDT
Recruiting Not applicable Interventional

Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)

NCT03138863
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary Artery Hypertension
Interventions
BALT GoldbBAL2 Detachable Balloon, Catheter System
Device
Lead sponsor
Rodrigo Ruano
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Miami, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 30, 2026, 2:42 PM EDT
Completed Not applicable Interventional Results available

The CHIPS Trial (Control of Hypertension In Pregnancy Study)

NCT01192412
View directory record Official record
Conditions
Gestational Hypertension
Interventions
Intervention is blood pressure management approach.
Procedure
Lead sponsor
University of British Columbia
Other
Eligibility
Female only
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
11
States / cities
New Haven, Connecticut • Louisville, Kentucky • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 30, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

NCT03473223
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Apolipoprotein A-I [human] (apoA-I), Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
18,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
202
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 30, 2026, 2:42 PM EDT
Terminated No phase listed Observational

Cerebral Hemodynamic Effects of Hypertonic Solutions in Severely Head-Injured Patients

NCT00125229
View directory record Official record
Conditions
Traumatic Brain Injury, Intracranial Hypertension
Interventions
Mannitol, Hypertonic Saline
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Sep 30, 2026, 2:42 PM EDT
Completed Phase 3 Interventional

Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension

NCT00273299
View directory record Official record
Conditions
Hypertension
Interventions
valsartan plus hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
607 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Sep 30, 2026, 2:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features

NCT02911701
View directory record Official record
Conditions
Pre-Eclampsia, HELLP Syndrome, Eclampsia
Interventions
Acetaminophen, Ibuprofen
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 30, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Using mHealth to Improve Adherence and Reduce Blood Pressure in Individuals With Hypertension and Mood Disorders

NCT04675593
View directory record Official record
Conditions
Bipolar Disorder, Non-Adherence, Medication, Hypertension, Major Depressive Disorder
Interventions
iTAB-CV, Self-Monitoring
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
21 Years to 80 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 30, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

NCT07511361
View directory record Official record
Conditions
Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Interventions
Tonlamarsen, Placebo
Drug
Lead sponsor
Kardigan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Arvada, Colorado • Homestead, Florida • Port Orange, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Sep 30, 2026, 2:42 PM EDT
Terminated Phase 4 Interventional

Acute Labetalol Use in Preeclampsia

NCT03872336
View directory record Official record
Conditions
Preeclampsia With Severe Features
Interventions
Experimental labetalol dose, Current standard of care
Drug · Other
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Sep 30, 2026, 2:42 PM EDT
Terminated Phase 3 Interventional Results available

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

NCT01392495
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Sep 30, 2026, 2:42 PM EDT